Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

This study will be conducted in 2 parts. Part 1 will evaluate LOXO-338 as monotherapy. If safety and initial evidence of efficacy of LOXO-338 monotherapy are confirmed, part 2 will evaluate the combination of LOXO-338 with the highly selective, noncovalent Bruton's tyrosine kinase (BTK) inhibitor, pirtobrutinib (LOXO-305).

Inclusion criteria

• B-cell malignancy.
• Patients must have received prior therapy.
• Patients must have an objective indication for therapy.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.
• Anticipated life expectancy of greater than or equal to (≥) 12 weeks.
• Adequate bone marrow function.
• Adequate hepatic function.
• Creatinine clearance of ≥ 60 milliliters (mL)/minute.
• Ability to swallow tablets.
• Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.
• Prior treatment-related adverse events (AEs) must have recovered to grade less than or equal to (≤) 1 or pretreatment baseline, with the exception of alopecia.
• Men with partners of childbearing potential or women of childbearing potential (WOCBP) must agree to use highly effective birth control.
• WOCBP must not be pregnant.
• Additional Inclusion Criteria for Patients with AL Amyloidosis

• In Part 1 Dose Expansion, patients with AL amyloidosis are eligible based on prior detection of primary systemic light-chain amyloidosis.
• Must have measurable disease of AL amyloidosis.
• Prior local fluorescence in-situ hybridization (FISH) testing results for t(11;14) are required to be submitted prior to enrollment.

Exclusion criteria

• Prior to identification of an appropriate RP2D (Dose Expansion) of LOXO-338, a history of known, active or suspected:

• Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocyticleukemia, or Hodgkin lymphoma
• Transformed low grade lymphoma
• Burkitt or Burkitt-like lymphoma
• Diffuse large B-cell lymphoma
• AL amyloidosis
• Multiple myeloma
• Lymphoblastic lymphoma or leukemia
• Posttransplant lymphoproliferative disorder
• Known or suspected history of central nervous system (CNS) involvement.
• History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within the past 60 days and with any of the following:

• Active graft versus host disease (GVHD)
• Cytopenias from incomplete blood cell count recovery post-transplant or CAR-T therapy
• Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity Grade > 1 from CAR-T therapy
• Ongoing immunosuppressive therapy
• Known human immunodeficiency virus (HIV) positive, regardless of cluster of differentiation 4 (CD4) count. Unknown or negative status eligible.
• Inability to take necessary uric acid lowering agents (i.e., allopurinol, rasburicase, orfebuxostat).
• Concurrent anticancer therapy.
• Concurrent treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers that can include antifungals.
• Use of ≥ 20 milligrams (mg) prednisone once a day (QD) or equivalent dose of steroid per day, within 7 days of start of study treatment. Patients may not be on any dose of prednisone intended for antineoplastic use.
• Vaccination with a live vaccine within 28 days prior to start of study therapy.
• Major surgery within four weeks of planned start of study therapy Prolongation of the QT interval corrected by Fridericia's Formula for heart rate (QTcF) greater than (>) 470 milliseconds (msec).
• Clinically significant cardiovascular disease.
• Female patient who is pregnant or lactating.
• Active second malignancy which may preclude assessment of DLT.
• Clinically significant active malabsorption syndrome including surgical resection of small intestine or other condition likely to affect gastrointestinal (GI) absorption of the orally administered study drugs.
• Active hepatitis B or C infection.
• Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal) or other clinically significant active disease process.
• Active uncontrolled auto-immune cytopenia.
• Additional Exclusion Criteria for Patients with AL Amyloidosis (Part 1 Dose-Expansion)

• Previous or current diagnosis of symptomatic MM.
• Heart failure that, in the opinion of the Investigator, is on the basis of ischemic heart disease.
• Supine systolic blood pressure < 90 mmHg, or symptomatic orthostatic hypotension in the absence of volume depletion.
• N-terminal pro hormone natriuretic peptide (NT-proBNP) > 8500 ng/L (or BNP > 700 ng/L if NT-proBNP is not available by local or central testing).
• Additional exclusion criteria for patients enrolled to part 2: LOXO-338 and pirtobrutinib combination

• Prior progression or intolerance to pirtobrutinib.
• Patients requiring therapeutic anticoagulation with warfarin.
• Known hypersensitivity to any component or excipient of pirtobrutinib.
• In patients with history of myocardial infarction or congestive heart failure, documented left ventricular ejection fraction (LVEF) by any method of ≤ 45 percent (%) in the 12 months prior to planned start of study treatment.
• History of uncontrolled or symptomatic arrhythmias including grade ≥ 3 arrhythmia on a prior BTK inhibitor.
• History of major bleeding on a prior BTK inhibitor.
• Current treatment with strong permeability glycoprotein (P-gp) inhibitors.